Skip to Main Content

Paper Details

Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn's Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies.
J Crohns Colitis
0
2024
APS, CD, Crohn's Disease, Crohn's disease, RZB, Risankizumab, SF, abdominal pain, interleukin-23, p19, patient, patients, risankizumab
Author NameAffiliation
Jean-Frederic ColombelIcahn School of Medicine at Mount Sinai
Stefan SchreiberUniversity Hospital Schleswig-Holstein, Kiel University
Marla C DubinskyIcahn School of Medicine at Mount Sinai
  • 1 - 3

Datasets

Release 1.2